Approval · Notice of Compliance 2563 · 2001
IMITREX: Notice of Compliance 2563
Issued July 18, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2563
- Date
- July 18, 2001
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in manufacturer name
- Therapeutic class
- 5-ht1 receptor agonist: migraine therapy
Products in this notice
Medicinal ingredients
- SUMATRIPTAN HEMISULFATE 5 MG per DOSE
- SUMATRIPTAN HEMISULFATE 20 MG per DOSE
- SUMATRIPTAN SUCCINATE 25 MG per TAB
- SUMATRIPTAN SUCCINATE 50 MG per TAB
- SUMATRIPTAN SUCCINATE 100 MG per TAB
- SUMATRIPTAN SUCCINATE 12 MG per ML